Dangerous Drug Tradjenta Under Investigation

BRAND NAME: Tradjenta

GENERIC NAME: linagliptin

The Food and Drug Administration approved a  Type 2 diabetes Drug called Tradjenta.

The drug, which is considered a DPP-4 inhibitor, is to be taken once a day and potentially in combination with other diabetes drugs.

Other drugs in the same diabetes class include Januvia and Onglyza.

How does Tradjenta work:

Tradjenta  is an anti-diabetic drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.

Although Tradjenta by itself usually does not cause low blood sugar (hypoglycemia), but low blood sugar may occur if this drug is prescribed with other anti-diabetic medications. It is always best to chat with your doctor about whether the dose of your other diabetic medication(s) needs to be lowered.

Tradjenta side effects: The side effects can include upper respiratory infection, sore throat, headache, muscle pain and even a stuffy or runny nose

This drug is still undergoing more tests, and based upon some research some people think it protects the heart others think that it increases the risk of pancreatitis and pre-cancerous cellular changes.

Status of Tradjenta Lawsuits according to Drug Watch

In May 2013, the Food and Drug Administration (FDA) alerted the public to the troubling research linking certain drugs, including Tradjenta, to pancreatitis and pancreatic duct metaplasia in type 2 diabetes patients. The FDA has asked the medical researchers to provide more information about their findings so that it can further investigate the risks.

Meanwhile, Tradjenta’s makers continue to market the drug, and it remains available by prescription. The FDA doesn’t necessarily take a drug off the market because of severe health risks. Drugmakers usually don’t recall dangerous drugs or update warning labels until many people have already been injured.

However, as is often the case, attention from independent medical researchers and injured consumers who file lawsuits can bring attention to previously undisclosed dangers and perhaps encourage a faster response. For this reason, lawsuits alleging Tradjenta injuries are expected to be filed in the coming month